Search research articles
Contact Us
Filters
Showing results (301-310 of 320) with videos related to
Page
of 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
ERJ Open Research
|
October 21, 2022
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) <i>versus</i> intercalated TKI with chemotherapy for <i>EGFR</i>-mutated nonsmall cell lung cancer
Rolof G P Gijtenbeek, Vincent van der Noort, Joachim G J V Aerts, et al.
Frontiers in Oncology
|
March 27, 2023
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J Sikkema, et al.
Targeted Oncology
|
April 20, 2023
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
Rob Ter Heine, Michel M van den Heuvel, Berber Piet, et al.
The Lancet. Respiratory Medicine
|
October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
Santiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.
The Lancet. Oncology
|
November 12, 2021
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
Sjoukje F Oosting, Astrid A M van der Veldt, Corine H GeurtsvanKessel, et al.
The New England Journal of Medicine
|
September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer
Jürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
Nature Communications
|
November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Jana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report
Anne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 320) with videos related to
Sort By:
Page
of 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
ERJ Open Research
|
October 21, 2022
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) <i>versus</i> intercalated TKI with chemotherapy for <i>EGFR</i>-mutated nonsmall cell lung cancer
Rolof G P Gijtenbeek, Vincent van der Noort, Joachim G J V Aerts, et al.
Frontiers in Oncology
|
March 27, 2023
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J Sikkema, et al.
Targeted Oncology
|
April 20, 2023
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
Rob Ter Heine, Michel M van den Heuvel, Berber Piet, et al.
The Lancet. Respiratory Medicine
|
October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
Santiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.
The Lancet. Oncology
|
November 12, 2021
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
Sjoukje F Oosting, Astrid A M van der Veldt, Corine H GeurtsvanKessel, et al.
The New England Journal of Medicine
|
September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer
Jürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
Nature Communications
|
November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Jana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report
Anne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.
Page
of 32